Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? by Crona, Daniel & Innocenti, Federico
Can knowledge of germline markers of toxicity optimize dosing
and efficacy of cancer therapy?
Daniel Crona1 and Federico Innocenti1,*
1Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel
Hill, NC, USA 27599-7361
Abstract
The systemic treatment of cancer with traditional cytotoxic chemotherapeutic agents and more
targeted agents is often complicated by the onset of adverse drug reactions. Pharmacogenetic
prediction of adverse drug reactions might have consequences for dosing and efficacy. This
review discusses relevant examples where the germline variant–toxicity relationship has been
validated as an initial step in developing clinically useful pharmacogenetic markers and provides
examples where germline variants have influenced dosing strategies and/or survival or other
outcomes of efficacy. This review will also provide insight into the reasons why more
pharmacogenetic markers have not been routinely integrated into clinical practice.
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It is well established that when cancer patients are administered chemotherapy, their clinical
response will vary greatly [1–3]. While many patients experience a complete or partial
response, for a sizable proportion of these patients the chemotherapy will be largely
ineffective despite the onset of toxicities, which might be severe and even life threatening.
Often, these adverse drug reactions (ADRs) will lead to hospitalizations [4]. Numerous
factors influence whether a patient will experience an ADR, including baseline clinical and
demographic characteristics and genetics. Among available efficacious regimens, the
selection of the safest regimen for a given patient is not guided by molecular biomarkers, but
rather by considerations related to the patient’s age, comorbidities and performance status.
Traditional cytotoxic chemotherapy and more novel molecularly targeted agents (some of
them are also called ‘biologics’) are the two core pharmacotherapeutic paradigms at the
center of modern cancer care. Phase I trials identify the dose-limiting toxicities (DLTs) of a
new chemotherapeutic agent, and doses are advanced until the onset of DLTs to define the
agent’s maximum tolerated dose (MTD) to be used in Phase II trials [5]. For most approved
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chemotherapeutic agents there is only one dose, rather than a dose range. This dose-
escalation design to discover the MTD intrinsically narrows the distance between toxic and
effective doses. It is natural to expect that one single dose might not be tolerated by some
patients and during the entire duration of the scheduled cycles of treatment. As a result, the
onset of serious grade 3 or 4 toxicities (as defined by the National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.03 [201]) can largely affect drug dosing
and dose intensity.
In all therapeutic areas, ADRs account for an estimated 7% of all hospital admissions, occur
in 10–20% of all patients and result in significantly increased hospital stays [6]. The costs to
the health system associated with ADR-related morbidity exceed US$3.6 billion annually in
the USA. ADRs are consistently among the top ten reasons for death among patients [7].
Several studies have reported on the incidence of cancer chemotherapy related ADRs. A
meta-analysis of 1219 colorectal cancer patients, who received 5-fluorouracil as part of their
regimen, revealed that up to 31% experienced grade 3–4 neutropenia [8]. A more recent
meta-analysis disclosed that approximately 30% of 2090 non-small-cell lung cancer
(NSCLC) patients who received docetaxel experienced grade 3–4 neutropenia [9]. It is
estimated that greater than 60,000 oncology patients are hospitalized due to severe
neutropenia and its complications each year in the USA, and that neutropenia is associated
with an inpatient mortality rate of 6.8% annually [6]. Dose–toxicity curves often differ
between traditional cytotoxic chemotherapies and targeted molecular agents, and efficacy
may occur in targeted agents at doses that do not cause significant toxicities [5]. Although
the development of dosing strategies for targeted agents and biologics are still largely
dependent on the identification of the MTD, there is significant debate concerning the
practicality of abandoning traditional dosing strategies in favor of the identification of a
minimal effective dose or the optimal biologic dose (OBD) [10]. OBD can be defined as the
dose associated with a prespecified most desirable effect on a biomarker among all doses
studied [5]. There are those who argue that the dosing of targeted agents should continue to
follow the traditional MTD dose-finding model as they believe that there is still a lack of
knowledge concerning OBD strategies [11]. However, others favor investigation of a
minimal effective dose [12] or OBD [13,14].
Since dose–toxicity curves and OBD dosing strategies for targeted agents could be starkly
different from traditional cytotoxic chemotherapy, the ADRs associated with these agents
are rarely life-threatening, but still no less serious. These drugs tend to be associated with
more nonhematological ADRs and less neutropenia than the traditional cytotoxics. ADRs,
which adversely affect quality of life and activities of daily living, can result in
noncompliance to oral targeted agents. For instance, a post approval survey of EGF receptor
(EGFR) inhibitors revealed that 76% of respondents were noncompliant to therapy due to
rash and that up to 32% of clinicians discontinued therapy due to rash [6]. Moreover, at least
11% of patients who receive cetuximab experience grade 3–4 rash [15], which could lead to
dose modifications by the clinician or nonadherence by the patient, and ultimately
complicate efficacy and survival outcomes. Up to 15% of patients treated with bevacizumab
experience grade 3–4 hypertension [6] and are at a significantly higher risk of grade 3–4
proteinuria and hypertension at both low and high doses [16].
These common ADRs are still very concerning as medication nonadherence compromises
dose intensity and ultimately survival [17,18]. Maintenance of dose intensity in patients for
the entire course of their treatment is extremely important; it has been shown both
prospectively and retrospectively, in a variety of tumor types, to be correlated with more
positive outcomes [19,20]. Dose intensity is a function of both dose and frequency, and
modifications to either chemotherapy dosing or frequency, as a result of ADRs, are
detrimental to outcomes [21]. Dosing is often adjusted based on renal or hepatic function,
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hematologic counts, results of basic metabolic panels, or drug levels measured in plasma. In
addition, chemotherapy package inserts also provide recommendations on how to adjust
dosing (usually dose reductions or dose interruptions) based upon the onset of toxicity.
Although very pragmatic, this approach of personalizing chemotherapy dose remains
inefficient, expensive and adversely affects the quality of life of patients. However, certain
ADRs have been researched as surrogate pharmacodynamic markers and seem to possess a
predictive role for chemotherapy response and efficacy. The relationship between drug-
induced rash and survival has been investigated in EGFR inhibitors, such as erlotinib [22–
26]. Likewise, the relationships linking drug-induced hypertension, the VEGF-pathway
inhibitor bevacizumab, and survival have been explored [27,28]. These studies support both
the paradigm that these specific ADRs are likely pharmacodynamic proxies for efficacy, and
the approach of dosing patients to OBD rather than MTD.
Pharmacogenetics examines interindividual genetic variability that influences the course of
drug action so that medication regimens may be optimized to maximize response, while
minimizing drug-induced toxicity. Personalized medicine through genetics and genomics is
the overarching goal for the field of pharmacogenetics and vital to the evolution of effective
treatment paradigms. The ability to predict and mitigate ADRs in oncology is of paramount
importance as a majority of chemotherapeutic agents are dosed to their MTD and possess a
narrow therapeutic index between efficacy and toxicity. There is currently a dearth of
clinically relevant prognostic and predictive pharmacogenetic markers derived from
germline variants that have been translated for routine incorporation into clinical practice
[29–31]. There is an opportunity to better understand the relationship between germline
variants, toxicity and chemotherapy dose so that more of these pharmacogenetic markers
may be utilized clinically to individualize therapies for cancer patients.
The purpose of this review is to analyze the available literature to elucidate pertinent
germline variant–ADR relationships and to describe how these associations may impact the
delivery of an optimal chemotherapy dose to patients and consequently affect survival
outcomes. We have chosen to systematically concentrate on a focused number of validated
germline pharmacogenetic variants that associate with ADRs and the manner in which those
variants might influence downstream effects, such as chemotherapy dosing and survival
outcomes. This review should not be construed as a complete evaluation of all
pharmacogenetic variants detailed in oncology-related literature, as this has been addressed
extensively in many recent reviews [32–34]. However, the resulting effects of these
associations on dosing and survival have never been analyzed in detail. For each specific
gene discussed, we will not review a comprehensive list of all alleles in each of the genes.
Rather, we have highlighted several specific pharmacogenetic variants that account for the
majority of variability in each gene to emphasize our approach.
Establishing the relationship between germline variants & toxicity
Validation of pharmacogenetic markers related to ADRs is of utmost importance to
clinicians to allow them to personalize the most efficacious and safe regimen for each
patient, without sacrificing dose intensity. With the advent of hypothesis-driven candidate
gene studies and more unbiased genome-wide approaches, oncology researchers have begun
to characterize the genetics that underlie serious ADRs. The labels for over 20
chemotherapeutic agents have been rewritten or revised to include information regarding
pharmacogenetic markers. Specifically, seven of these agents (6-mercaptopurine, 6-
thioguanine, 5-fluorouracil, capecitabine, irinotecan, nilotinib and imatinib) include
language describing a gene–toxicity relationship, which emphasizes the growing importance
of validating clinically useful pharmacogenetic markers to prevent the onset or mitigate the
severity of ADRs [202].
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Numerous pharmacogenetic studies have been conducted in an attempt to identify novel
germline variants that conclusively associate with ADRs. A majority of the validated
pharmacogenetic markers, and those primarily discussed in this review, are germline
variants that contribute to differences in drug metabolizing enzymes of drug inactivation. A
classic example is the thiopurine antimetabolite 6-mercaptopurine, an integral component in
the treatment of pediatric acute lymphoblastic leukemia (ALL) [35]. The antimetabolite, 6-
mercaptopurine, is activated in thioguanine nucleotides, which are then incorporated into the
DNA and interfere with the activity of nucleic acid-processing enzymes [35]. TPMT
inactivates 6-mercaptopurine through methylation. Genetic variations in the TPMT gene
(*2, *3A and *3C) lead to TPMT deficiency and reduced inactivation of 6-mercaptopurine
[36], and patients carrying these mutations usually have increased thioguanine nucleotide
erythrocyte levels [37,38].
The germline variant–toxicity relationship between UGT and irinotecan has also been
studied extensively. UGT1A1 is responsible for the inactivation of the active metabolite of
irinotecan through glucuronidation. Irinotecan is commonly used in advanced colorectal
cancer in combination with 5-fluorouracil. An inverse relationship exists between the
number of TA repeats in the UGT1A1 promoter and the transcriptional efficiency of the
gene [39], its protein [40] and mRNA expression [41], and the level of glucuronidation of
the active metabolite of irinotecan [42,43]. UGT1A1-deficient patients are homozygous
carriers of the *28 variant (seven TA repeats, versus six repeats in 1*1). In addition, the
germline variant–toxicity relationship has been validated between dihydropyrimidine
dehydrogenase (DPD) and fluoropyrimidines. Both 5-fluorouracil and its oral equivalent
capecitabine are routinely used in the treatment of gastroesophageal, hepatocellular and
colorectal cancers. DPD is responsible for up to 85% of the catabolism of fluoropyrimidine
antimetabolites [29], and the DPYD*2A variant has been associated with decreased DPD
catabolic activity.
The germline variants described above are associated with increased risk of myelotoxicity
(most notably neutropenia), as well as other potentially lethal clinical sequelae.
Myelosuppression is often the DLT of many chemotherapeutic agents due to their
mechanisms of action, which target highly replicating cells such as those of the bone
marrow. Neutropenia can be routinely measured and quantified, which increases the ability
to characterize pharmacodynamic effects of these medications with relative precision.
Complications associated with neutropenia (i.e., infection and sepsis) are associated with
poorer outcomes and increased costs to the health system. It has been estimated that the cost
of inpatient treatment of neutropenia for one patient exceeds US$13,000 per hospitalization
[44]. Overall, severe neutropenia has a detrimental effect on dose intensity, not only in terms
of the drug causing neutropenia but also to all other combined chemotherapies administered
as part of that regimen [19,45]. TPMT-deficient patients are at greater risk for 6-
mercaptopurine-induced ADRs, mainly that of severe myelosuppression [37,38]. The
positive predictive value of the TPMT genotype test has been estimated to be 67–100% [46].
UGT1A1-deficient patients are at a 9.3-fold higher risk for the development of irinotecan-
induced grade 4 neutropenia than patients with nondeficient UGT1A1 activity [47]. The
positive predictive value of a UGTA1A1*28/*28 genotype to detect grade 3–4 toxicity has
been estimated to be 50% [48]. Approximately 20–50% of patients who experience a grade
3–4 ADR are carriers of DPYD*2A [49–52], and exhibit decreased DPD activity [52]. They
have a 3.4-fold higher risk for grade 4 neutropenia when compared with patients with
normal DPD activity [53]. The positive predictive value of DPYD*2A for grade 3–4 toxicity
has been estimated at 46% [54].
Germline variants have also been associated with chemotherapy-induced ADRs other than
myelotoxicities, such as neutropenia. Genetic associations have been investigated linking
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hypertension with bevacizumab and skin toxicities with EGFR inhibitors (i.e., cetuximab,
panitumumab, erlotinib and gefitinib). Skin rash has been reported in approximately 80% of
patients taking these drugs [55]. Inhibition of EGFR signaling in basal keratinocytes leads to
abnormalities in cell growth, differentiation and maturation, as well as an inflammatory
response, which ultimately leads to the onset of rash [56]. One proposed germline
polymorphism associated with skin rash is a CA dinucleotide repeat in intron 1 of EGFR
[57]. The number of CA repeats is inversely proportional to expression of EGFR, and
shorter CA repeats have been linked to greater incidence of skin toxicity [58–60].
Bevacizumab is a monoclonal antibody that binds to VEGF and inhibits angiogenesis.
Evidence suggests a link between hypertension and impaired angiogenesis [61], and
treatment with bevacizumab has been associated with increased incidence of grade 3–4
hypertension [16,62,63]. A meta-analysis of 12,656 patients demonstrated that bevacizumab
significantly increases the risk of all-grade hypertension by 23.6% (95% CI: 20.5–27.1%)
and grade 3–4 hypertension by 7.9% (95% CI: 6.1–10.2%), relative to control patients on
concurrent traditional chemotherapies [63]. In another study of patients who took
bevacizumab, two VEGF germline genotypes (-634CC and -1498TT) were associated with
lower rates of grade 3–4 hypertension [64]. This was the first trial to investigate biomarkers
associated with bevacizumab-induced hypertension. Emerging data have confirmed a similar
relationship and showed that patients with either the -634CC or -1498TT genotypes who
were treated with the VEGF-pathway inhibitor sunitinib had less incidence of hypertension
(p = 0.03, in both cases) [65]. Nevertheless, at this stage, the variants in EGFR and VEGF
require additional validation before they can be used as predictive markers of toxicity.
The process of pharmacogenetic marker validation still faces several major hurdles before
these markers are integrated into routine clinical practice. Conflicting data generated from
pharmacogenetic trials have been reported for many of the most well-characterized potential
markers. For example, the UGT1A1*28/*28 genotype was not associated with severe
diarrhea (another common side effect of irinotecan) in one study, but it was in others
[47,66,67]. In addition, inconsistencies concerning the functional variant associated with a
particular ADR complicate the validation of pharmacogenetic markers. For example, data
points to -216G/T and -191C/A EGFR variants, rather than C A dinucleotide repeats in
intron 1, as the causative single nucleotide polymorphisms responsible for EGFR inhibitor-
induced skin toxicity [57]. The relationship between 5-fluorouracil toxicity and DPYD*2A
also illustrates another problem in the process of pharmacogenetic marker validation: rare
germline variants, which have limited predictive power. Data suggests that alternate
germline variants in DPYD [68], noncoding region genomic variants found through
haplotype assessment [69], DPYD promoter hypermethylation [70–72], or the influences of
TYMS, MTHFR and other genes [29,33], may play a significant role in explaining the
remainder of the germline variant–toxicity relationship involving neutropenia and 5-
fluorouracil.
Effect of the germline variant–toxicity relationship on chemotherapy dosing
While over 20 chemotherapeutic agents have references to pharmacogenetic markers in their
FDA label [202], a clear disconnect exists between these pharmacogenetic markers and
dosing recommendations [73]. Only 6-mercaptopurine, 6-thioguanine, nilotinib and
irinotecan include pharmacogenetic-based dose-reduction recommendations in their drug
labels [73]. However, given the limited scale of clinical investigations on genotype-based
dose individualization, they did not recommend mandated pharmacogenetic testing, nor did
they provide guidance concerning the optimal timing for testing. This same limited scale of
clinical investigations led the FDA to exclude explicit dose-reduction guidelines from the
irinotecan or 6-mercaptopurine labels [73]. While the package insert for irinotecan includes
language endorsing dose reductions by one level for patients with the UGT1A1*28/*28
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genotype, these recommendations are not sufficiently specific [74]. Genotype-based dose-
modification information should be far more precise as vague dose reduction language could
conceivably compromise the efficacy of irinotecan if clinicians reduce doses too much.
Despite the fact that the 6-mercaptopurine label does not contain specific dose reductions
based on genotype, accumulating data regarding its dosing in TPMT-deficient heterozygous
[75] and homozygous [76] patients led to guidelines supporting 50% and at least 90%
reductions, respectively, of the initial dose of 6-mercaptopurine in pediatric patients treated
for ALL. This genotype-based dosing strategy has successfully limited ADRs [77]. These
conclusions were based on studies showing that TPMT-deficient heterozygotes can tolerate
65% of the standard 75 mg/m2 6-mercaptopurine dose used in pediatric ALL (50 mg/m2
daily) [76,78,79], while homozygotes can receive one tenth to one fifteenth o f t he standard
dose (i.e., 10 mg/m2 every third day) [75]. In subsequent studies, patients were prospectively
screened for TPMT status, and doses of 6-mercaptopurine were reduced in patients with
TPMT-deficient alleles, according to a prespecified dosing algorithm [80,81]. As a result,
these patients were successfully treated with 6-mercaptopurine, with rates of grade 3–4
ADRs comparable with patients with wild-type TPMT [77]. In addition, the identification of
TPMT-deficient patients not only permits clinicians to rationally reduce doses of 6-
mercaptopurine to avoid severe ADRs, it also allows them to preserve the dose intensity of
the regimen by administering concurrent chemotherapies at unadjusted doses and without
interruptions [82,83].
The irinotecan doses used in current regimens were previously identified through Phase I
development without stratifying patients for UGT1A1*28. It has been postulated that the
dose of irinotecan might be suboptimal in patients with *1/*28 and *1/*1 genotypes, and
that these patients may benefit from higher, safe doses. This hypothesis has been tested in
colorectal cancer patients treated with irinotecan combined with 5-fluorouracil (folinic acid,
fluorouracil and irinotecan regimen) [84]. Dose-escalation of irinotecan was assessed in *1/
*1 and *1/*28 patients, and results from these studies showed they were safely and
effectively treated with irinotecan doses of 370 and 310 mg/m2, respectively. These doses
were considerably higher than the 180 mg/m2 dose currently used in the clinic. Similar dose
levels were safely given in another study of folinic acid, fluorouracil and irinotecan regimen
(390 and 340 mg/m2, respectively) [85]. This study also demonstrated that the MTD for *28/
*28 patients was 130 mg/m2, which is 30% lower than the standard dose. A similar
conclusion has been also obtained in Japanese patients with *28 and/or *6 alleles, the
common deficient alleles in Asians. Patients with *28/*28, *28/*6 and*6/*6 also achieved
an MTD of 150 mg/m2 [86]. Meta-analyses demonstrated that *28/*28 patients have a
significantly higher risk for grade 3–4 neutropenia when compared with *1/*28 and *1/*1
patients at low doses (relative risk = 2.43; p = 0.003) [87], medium doses (odds ratio [OR] =
3.22; p = 0.008) and high doses (OR = 27.8; p = 0.005) of irinotecan [88].
There are additional examples where a germline variant–toxicity relationship might alter
dosing. In a capecitabine study of 568 patients with advanced colorectal cancer, all of the
patients with DPYD*2A experienced at least one grade 3–4 ADR (mostly diarrhea) [89].
The cumulative percentage dose reduction in these patients was significantly higher (50%)
than wild-type patients (10%). For EGFR and VEGF-pathway inhibitors, there are no data
on the effect of variants for skin rash and hypertension (respectively) on dosing and dose
intensity. This represents a significant gap in current knowledge that should be addressed.
The downstream effect of germline variants of toxicity on dosing & efficacy
The assumption that patients should be treated at the highest, safe doses of chemotherapy is
still the foundation of a successful treatment regimen. Although we believe a
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pharmacogenetic marker of toxicity has high clinical utility, translation of such markers to
clinical practice will be increased dramatically if ADRs can be linked to efficacy and
survival. Currently, only the example of TPMT and 6-mercaptopurine exists where the
knowledge of a germline variant–toxicity-dosing relationship is a tool to optimize efficacy.
When 6-mercaptopurine doses were determined prospectively, based on TPMT genetic
status, relapse rates were not significantly different between wild-type patients and those
with TPMT-deficient genotypes (13.2 ± 2.3% vs 6.7 ± 6.7%; p = 0.46). In addition, patients
with TPMT-deficient genotypes were not at significantly higher rates of grade 3–4
neutropenia when compared with wild-type patients (OR = 1.4; 95% CI: 0.3– 6.9; p = 0.71)
[77,79]. Most importantly, this genotype-based dosing strategy has successfully limited
potentially life-threatening ADRs, while not sacrificing efficacy in this patient population
[77,82]. The interaction between 6-mercaptopurine and the bone marrow is unique as it is
not only activated intracellularly in the bone marrow, but is also the site for its antileukemic
efficacy and its myelotoxic DLT. This idiosyncrasy of 6-mercaptopurine allows the
downstream effects of TPMT genetics on survival to be more directly assessable. But aside
from the TPMT example, the relationship between germline variant–toxicity, chemotherapy
dosing and survival outcomes have been extremely difficult to establish. For other
relationships, the consequences on survival are tested as a secondary end point or have not
been tested at all in clinical trials.
Very few genotype-driven dose-optimization studies have prospectively assessed objective
response rate, progression-free survival, overall survival or other measures of efficacy as
their primary end points. For example, little evidence exists to conclusively link UGT1A1
germline variants to ADRs, dose and survival. In a retrospective analysis, dose reductions of
irinotecan due to UGT1A1*28-related toxicity did not affect progression-free survival (10 vs
11 months) or overall survival (19 vs 18 months) [90]. A second study retrospectively
evaluated the association between UGT1A1 genotype, prevalence of grade 3–4 toxicity and
survival outcomes in colorectal cancer patients treated with irinotecan. This study
demonstrated a significantly higher rate of ADRs, coupled with worse survival, for the *28/
*28 patients. Grade 3–4 neutropenia was significantly more common in *28/*28 patients
(24% compared with 8.2 and 5.5% in the *1/*28 and *1/*1 genotypes, respectively; p =
0.019), while the median overall survival for the three genotypes was also significantly
different (2.4, 2.0 and 1.6 years for the *1/*1, *1/*28 and *28/*28 genotypes, respectively; p
= 0.008) [91]. It is currently unclear whether the results of this study point to a true
downstream effect of the *28/*28 genotype–neutropenia relationship on survival, or if the
decrease in median overall survival for patients with the *28/*28 genotype is simply due to
neutropenia-induced dose modifications that decrease overall exposure to irinotecan. Two
recent studies of irinotecan, dose-escalated by genotype, showed that patients receiving
higher doses experienced higher response rates than those treated at lower doses. In the first
study, 65% of the patients treated with doses greater than or equal to the MTD of irinotecan
achieved a complete or partial response compared with only 25% of patients treated with
doses below the MTD of irinotecan (p = 0.014). Irinotecan dosed above MTD was an
independent predictor of response in these patients (OR = 4.38; 95% CI: 1.13–17.03; p =
0.03). Median time to progression was not significantly different between the patients
treated above and below the irinotecan MTD (hazard ratio = 0.85; 95% CI: 0.40–1.80) [84].
In the second study, 67% of patients treated with irinotecan doses ≥260 mg/m2 achieved a
complete or total response, compared with only 24% of patients treated with doses <260 mg/
m2 (p = 0.001). However, unlike the previous study, the median time to progression was
higher in patients treated with doses ≥260 mg/m2 when compared with patients treated with
<260 mg/m2 (16 vs 7 months; p = 0.003) [85]. These data are premature, and prospective
intervention studies should test the superiority of genotype-driven dosing of irinotecan
versus standard dosing in relation to survival in metastatic colorectal cancer.
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The evidence is still too sparse to provide a complete understanding of the relationship
between germline variants associated with ADRs and survival in patients treated with EGFR
and VEGF-pathway inhibitors, largely due to a lack of validated single nucleotide
polymorphisms predictive of toxicity. Several Phase II–III studies have linked the
occurrence and severity of EGFR inhibitor-induced rash to improvements in survival [22–
25,92]. One notable Phase III trial of NSCLC patients revealed a substantial survival benefit
when patients experienced grade 2 and 3 rash compared with when no rash was observed (7
and 11 months, respectively, vs 3 months) [22]. Moreover, several studies have reported an
association between higher response and survival with fewer CA repeats (independent from
the effects of skin rash or other toxicities) [57,93], while other studies have failed to validate
this relationship [94]. A prospective Phase II dose-driven erlotinib study in NSCLC patients
attempted to discover whether dose escalation beyond MTD would confer a survival
advantage. The results from this dose-to-rash erlotinib dosing study revealed that all patients
who achieved at least a partial response also experienced rash. Progression-free survival was
significantly extended in patients who experienced grade 2 rash when compared with
patients without rash (3.5 vs 1.9 months; hazard ratio = 0.52; p = 0.05) [26]. However, this
study did not investigate the role of germline variants on incidence and severity of rash, dose
escalation or survival. Furthermore, the effects of dose reductions of EGFR inhibitors, as a
result of grade 3–4 rash, on efficacy and survival have not been assessed. Clearly in the case
of EGFR inhibitors, the germline variant–rash–dose-escalation (or reduction) relationship
and its effects on efficacy and survival require further and deeper examination.
Studies of patient populations have linked the incidence of bevacizumab-induced grade 3 – 4
hypertension to improved survival outcomes [27,28]. More recently, associations between
VEGF variants and survival have been explored [95,96]. A trial of advanced breast cancer
patients treated with bevacizumab tested VEGF germline variants (-634G/C, -1498T/C,
-2578C/A and -1154G/A) for associations with hypertension and survival. This study
demonstrated that patients with the -634CC and 1498TT genotypes who experienced grade
3–4 hypertension achieved superior median overall survival compared with patients with no
hypertension (38.7 vs 25.3 months; p = 0.002), while the -634G/C and -1498C/T variants
were not associated with improved survival [64]. However, the results of these associations
have not been readily replicated, and data from other studies have associated improved
survival outcomes with the -634GG [96] and 1498CC genotypes [97]. However, data from
this trial did reveal the potentially important impact of the -2578AA and -1154AA
genotypes on improved survival outcomes [64]. The -2578A and the -1498T alleles are in
high linkage disequilibrium in the 1000 Genomes reference population of Caucasians
(Linkage disequilibrium: r2= 0.966) [98]. This suggests that a linkage disequilibrium block
of genetic variation containing these variants may impact both phenotypes, and could
potentially be useful as predictive markers of both hypertension and survival.
High VEGF expression and microvascular density have been associated with decreased
survival [99], and the results from the previous study showed that the -2578A allele trended
toward lower VEGF expression [64]. A plausible mechanistic explanation is that the
-2578AA genotype causes lower VEGF expression and that lower levels of VEGF may slow
angiogenesis and the vascularization of the tumor, therefore contributing to increased
survival. A similar process may also account for bevacizumab-induced hypertension. It can
be postulated that inhibition of the VEGF pathway, as a result of bevacizumab
administration and in combination with the -1498TT and -634CC genotypes, may result in
impaired vascularization. Lower VEGF levels leads to rarefaction (a process that results in
reduced microvascular density), increased peripheral vascular resistance and ultimately the
onset of hypertension [61]. The impact of these germline variants, in terms of their effects
on hypertension and survival, has just begun to be analyzed in studies of other VEGF-
pathway inhibitors, including sunitinib [65]. Such studies could be extremely useful to
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prioritize validation of these variants in patients prescribed other targeted therapies from this
class, which all share similar rates of high-grade hypertension. These findings exemplify the
challenges facing researchers and clinicians, and illustrate the difficulty in applying such
information to guide dosing. Although we have started to understand the intricacy of the
effects of VEGF genetic variation on both hypertension and survival, more efforts should
address whether genotype-driven hypertension of bevacizumab or sunitinib can negatively
impact dosing and compromise survival.
Conclusion
Incorporation of validated pharmacogenetic markers into routine practice is of paramount
importance to clinicians as they strive to reduce severe and life-threatening ADRs.
Prevention and mitigation of ADRs improves patient quality of life and compliance to
chemotherapy, which ultimately may lead to better survival outcomes. Understanding the
putative relationship between germline variants, ADRs, chemotherapy dosing and survival is
essential to the identification and translation of pharmacogenetic markers. We believe that
any validation approach of pharmacogenetic markers, with potential clinical utility, must
reflect incorporation of these four key components.
The examples of TPMT and 6-mercaptopurine, UGT1A1*28 and irinotecan, DPYD and the
fluoropyrimidines, EGFR and EGFR inhibitors, and VEGF and VEGF-pathway inhibitors
provide illustrations of the varying levels of success that researchers and clinicians have had
in translating pharmacogenetic molecular markers to the clinic. Currently, the example of
prospective TPMT screening and subsequent dose adjustments in pediatric ALL patients has
been the model for pharmacogenetic success in oncology. Increased numbers of prospective
clinical trials, similar to those used to justify prospective TPMT testing, are direly needed to
validate many more pharmacogenetic markers. Moreover, specific dosing recommendations
need to be included into drug labels to help guide clinician decision-making processes.
Dosing recommendations based on TPMT and UGT1A1 genotypes should be clarified and
prospective trials should be conducted to solidify the relationship linking DPYD, EGFR and
VEGF variants to ADRs.
While a few smaller trials have explored the effect of genotype on ADRs, dosing and
survival, only a handful of studies have conducted well-powered prospective trials to
explore this relationship. This could be due to a number of reasons, ranging from low
frequency of a particular germline variant (i.e., DPYD*2), to a lack of a convincing body of
evidence conclusively linking a germline variant to ADRs and dose modifications (i.e.,
EGFR- and VEGF-pathway inhibitor germline variants). The DPYD example illustrates how
the current approach of trying to identify highly penetrant, single gene variants to explain
complex phenotypes (such as ADRs) and to be used as pharmacogenetic markers, may be
partially flawed. Research to identify novel markers may rely on more sophisticated
methods to characterize polygenic effects. In addition, research to identify translatable
pharmacogenetic makers with downstream effects on survival may be complicated by the
inability to take into account the effects of somatic mutations, tumor heterogeneity,
epigenetic factors or other undiscovered prognostic confounders. However, identification of
pharmacogenetic markers, validated through approaches that consider the germline variant–
toxicity–survival relationship, will help clinicians craft strategies that rationally dose drugs
within an enlarged therapeutic window to optimize efficacy while mitigating ADRs.
Future perspectives
Adoption of validated pharmacogenetic markers into routine clinical practice has been slow,
in part due to the scarcity of genotype-driven trials that implement the approach we have
Crona and Innocenti Page 9













outlined. As the field of pharmacogenetics continues to evolve, retrospective meta-analyses
of promising gene variants might validate or refute their use in the clinic. Prospective
interventional studies involving patients stratified by genotype will be a means of
systematically collecting phenotype data, while also collecting data on potential
confounding factors that would inhibit translation of germline variants into clinically useful
pharmacogenetic markers. Finally, secondary pharmacogenetically-driven posthoc analyses
of Phase III studies (which are sufficiently powered for genomic analysis) will further
analyze the relationship between genetics, dosing strategies, ADRs and survival outcomes.
Candidate gene and genome-wide association studies are two methods that will continue to
drive identification of pharmacogenetic markers [100]. As the number of approved oral
chemotherapeutic medications increases, strategies based on germline variant–toxicity–dose
paradigms need to be developed to help identify patients at increased risk for the onset of
common ADRs that adversely affect patient quality of life and compliance to therapy.
Existing statistical models might aid in the process of elucidating the links that connect
germline variants to toxicity, dosing and survival. These relationships will be better
understood by evaluating a cumulative incidence of an event in the context of a regression
model of competing risks. Interdependence of variables limits the ability of existing
statistical models to extricate one event of interest, for analysis, from all other competing
risks. Frequently in cancer studies, several competing events (phenotypes) are present that
cause treatment failures. The event of interest might occur later in treatment than the
occurrence of severe ADRs, disease progression or death, which could result in early
withdrawal from the study. Use of a standard case–control approach for analyzing the data
might be flawed as competing risks and cumulative incidences are ignored, and has the
potential to shroud the identification of pharmacogenetic markers. In recent years, cancer
researchers have successfully implemented novel methodologies [101,102] into cumulative
incidence competing risks models in their analyses [28,103–105]. Future studies that analyze
pharmacogenetic markers, should employ these types of analyses because the intricacies of
the model allow for a more accurate depiction of probabilities of events of interest occurring
in the presence of competing risks. By employing this statistical model, researchers will be
able to compare cumulative incidence curves between two or more groups, stratified by
genotype, for a phenotype of interest.
Another reason for the slow inclusion of pharmacogenetic biomarkers into clinic is the
conspicuous absence of explicit pharmacogenetic-based dosing guidelines published by
regulatory bodies. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of
the NIH’s Pharmacogenomics Research Network [203] and the Pharmacogenomics
Knowledge Base [204] provide peer-reviewed, updated, evidence-based, freely accessible
pharmacogenetic guidelines for chemotherapeutic agents [84]. These guidelines will
facilitate the translation of knowledge derived from laboratory-based pharmacogenetic and
pharmacogenomic research into the clinic, and provide explicit instructions regarding dosing
and testing of these agents. Dosing information will be customized for patients based on
treatment response. Guidelines have already been developed for TPMT and 6-thioguanine
and 6-mercaptopurine dosing [85], but the CPIC and other consortia will continue to
develop guidelines for gene–chemotherapy pairings into the future. In addition to CPIC,
other consortia, such as the Pharmacogenetics Working Group from the Netherlands, will
also continue to publish pharmacogenetic-based dosing guidelines for chemotherapy and
targeted agents. To date, the Pharmacogenetics Working Group has published dosing
guidelines for tamoxifen, irinotecan, 6-mercaptopurine and 5-fluorouracil/capecitabine,
based on pharmacogenetic markers, but will continue to publish guidelines that will
complement the work of the CPIC and PharmGKB [106]. Published pharmacogenetic-based
dosing guidelines will undoubtedly aid clinicians in the optimization of treatment efficacy,
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mitigation of toxicity, and improvement of both medication adherence as well as quality of
life for patients taking chemotherapy.
Finally, interethnic differences in the distribution of variant alleles could also potentially
obstruct the adoption of pharmacogenomic standards and impede adoption of
pharmacogenetic biomarkers into the clinic. Projects, such as the Pharmacogenomics for
Every Nation Initiative [205], will serve to address interethnic differences in allele
frequency distributions. Currently, the Pharmacogenomics for Every Nation Initiative has
established regional centers in six countries, and is determining allele frequencies of known
polymorphisms in different populations. Ultimately, initiatives like the Pharmacogenomics
for Every Nation Initiative will help identify interethnic differences that aid in medication
formulary decisions, population stratification in genotype-driven clinical trials, and even
target identification early-on in the global drug development process.
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• Adverse drug reactions (ADRs) account for 7% of all hospital admissions, occur
in 10–20% of all patients and increase hospital stays.
• ADR-related morbidity exceeds US$3.6 billion annually in the USA.
• Prevention and mitigation of ADRs improves quality of life and medication
adherence, and may lead to better survival outcomes.
Chemotherapy dose
• Maintaining dose for the entire course of treatment has been shown
prospectively and retrospectively in various tumor types to be correlated with
better outcomes.
• Traditional cytotoxic chemotherapies are dosed to maximum tolerated dose, but
novel molecularly targeted agents could be dosed to optimal biologic dose.
TPMT & 6-mercaptopurine
• Reduced TPMT function places patients at significantly greater risk for 6-
mercaptopurine-induced ADRs, including neutropenia.
• Patients heterozygous and homozygous for reduced TPMT function alleles
receive 50 and ≥90% reductions of the initial dose of 6-mercaptopurine,
respectively.
• Dose reductions in patients with reduced TPMT function results in less grade 3–
4 neutropenia, while preserving positive survival outcomes.
UGT1A1& irinotecan
• UGTA1A1*28/*28 patients are at a significantly higher risk for grade 3–4
neutropenia at low and medium doses of irinotecan when compared with
UGTA1A1*1/*28 and UGTA1A1*1/*1 patients.
• UGT1A1*1 patients were able to tolerate doses that exceed the standard
irinotecan maximum tolerated dose, and dose reductions for UGT1A1*28
patients due to neutropenia did not compromise survival outcomes.
• Explicit dosing recommendations for patients with UGT1A1*1 versus
UGT1A1*28 have not yet been published.
DPYD & 5-fluorouracil/capecitabine
• Germline variants in DPYD have been associated with increased ADRs.
• The DPYD*2 allele is not prevalent in the general population, but is associated
with a 3.4-fold higher risk for grade 4 neutropenia compared with patients with
normal dihydropyrimidine dehydrogenase activity.
• The relationship between DPYD*2 genotype, grade 3–4 neutropenia and
survival remains unclear and requires further investigation.
EGF receptor & erlotinib/cetuximab
• Skin rash is an ADR that is experienced by approximately 80% of patients
taking EGF receptor (EGFR) inhibitors.
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• A CA repeat in the intron 1 region of EGFR has been associated with increased
incidence of rash in patients taking EGFR inhibitors.
• Increased incidence of rash has been associated with increased progression-free
survival.
• The role of germline variants in EGFR inhibitor-induced rash, dosing and
survival remains unclear.
VEGF & bevacizumab
• Correlations between bevacizumab-induced hypertension and improved survival
outcomes may be related to germline variations in the VEGF pathway.
• VEGF germline variants have been associated with decreased incidence of
hypertension (-634CC and -1498TT) and increased survival (-2578AA and
-1154AA).
• The relationship between VEGF-pathway germline variants and bevacizumab
dosing is still unclear.
Conclusion
• Any approach to clinical validation of pharmacogenetic markers must reflect an
understanding of the relationships between germline variants, ADRs,
chemotherapy dosing and survival.
• Consortia, such as the Pharmacogenomics Knowledge Base, the Clinical
Pharmacogenetics Implementation Consortium and the Pharmacogenetics
Working Group will provide pharmacogenetically-based dosing
recommendations for chemotherapeutics and aid in the translation of
pharmacogenetic markers into clinical practice.
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